It’s the second advancement of RSV technology this week—with more expected soon. ICYMI: The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has been reviewing much-needed vaccines for respiratory syncytial virus (RSV) and recommended Pfizer’s vaccine for older adults on Tuesday.
Yesterday, the committee backed GSK’s vaccine—voting to recommend the vaccine for older adults. The FDA is expected to decide on approval by May 3.
What they’re saying: “Today’s vote brings us an important step closer to delivering one of the world’s first vaccines for RSV, a respiratory virus that causes potentially debilitating disease and imposes a major burden on healthcare systems. Thousands of older adults in the US are impacted by RSV and those with underlying health conditions, like respiratory and heart diseases and diabetes, are at increased risk of severe complications,” said Phil Dormitzer, Global Head of Vaccines R&D at GSK.
More reading: 2023 is shaping up to be the year of RSV—in a good way
